Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05RGV
|
|||
| Former ID |
DNCL002473
|
|||
| Drug Name |
MK-1496
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Merck
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H24N2O
|
|||
| Canonical SMILES |
CC(C1=CC=C(C=C1)C(CNC(C)(C)C)O)N
|
|||
| InChI |
1S/C14H24N2O/c1-10(15)11-5-7-12(8-6-11)13(17)9-16-14(2,3)4/h5-8,10,13,16-17H,9,15H2,1-4H3/t10-,13+/m0/s1
|
|||
| InChIKey |
KUHBBYPXWKYKKR-GXFFZTMASA-N
|
|||
| CAS Number |
CAS 1037254-47-9
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00880568) Phase I Study of MK-1496 in Patients With Advanced Solid Tumor (MK-1496-002 AM 4)(COMPLETED). U.S. National Institutes of Health. | |||
| REF 2 | J Clin Oncol 29: 2011 (suppl; abstr 3012). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.